- Joined
- 31 August 2009
- Posts
- 376
- Reactions
- 1
I agree vulture, but OBJ was loaded up to the hilt with short term traders, any change that delays timeline causes them to exit rapidly.
In actual fact its the 2nd best result OBJ could have wanted and was already priced in imo.
The best result would be a full commercial venture, but its a bit premature for that, so this in reality shows great confidence in OBJ transdermal patch. Given 3M simultaneously have attempted to employ an entire transdermal division things still look very promising for 3M, i actually dumped mine near the low today. More of a capital protection measure. I think they will test new lows again before some common sense prevails. Its only opinion so DYOR.
I will probably re enter towards the end of this trial.
I was very fortunate to get out at .043c after a skim read of the announcement, came to the part which said 6 month extension and was out not much later, a lot of churning and burning in the five minutes that followed. I agree it will come back, they seem to slip an announcement out every so often to keep things lively.
Lot of activity today & a 60% hike in sp...
>>>>>
OBJ Limited (ASX: OBJ) is pleased to announce that GlaxoSmithKline Consumer Healthcare (GSK) has informed the Company of its desire to proceed with an FIMTM development program in a major consumer healthcare sector following a sequence of successful technology evaluations. The target application for the FIMTM development is a key sector in consumer healthcare.
GlaxoSmithKline Consumer Healthcare has issued the following statement.
“GlaxoSmithKline Consumer Healthcare (GSK) has reported statistically significant levels of enhancement in an in vitro testing model by the OBJ technology in a global Consumer Healthcare application. These results are the outcomes of the short term evaluation agreement with GSK announced to shareholders on 18th February 2010.
GSK and OBJ are now in discussions regarding the next steps of this program which will include a technology integration program and in vivo human efficacy testing to quantify the business opportunity"
Background to the Announcement:
GSK and OBJ have collaborated in consumer healthcare applications since 2006 and the current discussions for the establishment of a major FIMTM product development program are the next steps in one of those programs.
The Consumer Healthcare program under discussion will include a design and development stage to build OBJ's FIMTM technology into a common household consumer product. These will then be used in human efficacy studies to demonstrate the level of consumer benefit provided by the FIMTM technology and consumer acceptance testing to determine marketability within the US$29 billion market sector. These programs will be used to quantify the size of the potential international market and to determine the resources necessary to exploit the commercial opportunity.
>>>>>
Been a lot of hype with this stock with the speculator back in 09 & early 10, this feasibility study sounds a pretty big deal- anyone any thoughts??
wish I had listened to my own advice (back a couple of posts) and bought more when it bounced off 2.0c (it then went to 3.8c when that ann suprised everyone). doh!
I was stuck back up at 3.0c though so I was glad to get out when it went back up. It subsequently settled back down to and bounced off support at 2.5c
People are buying up now ahead of the agm I hear. A 1-for-1 oppie offer is on the table but they haven't announced the record date.
If it goes through there could be a big sell off after the allotment yeah?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?